The selection of CLEC14A in models of pancreatic and lung carcinomas, as well as the human prostate-specific membrane antigen (PSMA), expressed on malignant vasculature of various tumors or the neoangiogenesis-associated αvβ3 integrin, demonstrated further promising antigen options for future CAR T-cell constructs [101–103]. The gene discussed is FOLH1; the disease is lung carcinoma.